Aurora Cannabis expands Leuna, Germany EU-GMP facility, doubling expected annual flower output
Bitget2026/10/08 11:06Aurora Cannabis completed a major expansion of its EU-GMP facility in Leuna, Germany, more than doubling expected annual flower output. Multi-million-dollar investment lifts domestic cultivation capacity in Germany, strengthening supply for the country’s fast-growing medical market. Site renamed Aurora Horizon, positioned as a core node in the group’s European manufacturing network to support broader regional demand growth. Expanded areas received an updated EU-GMP license, clearing production scale-up for compliant distribution across European markets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurora Cannabis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: TO66033) on October 08, 2026, and is solely responsible for the information contained therein.
- Aurora Cannabis completed a major expansion of its EU-GMP facility in Leuna, Germany, more than doubling expected annual flower output.
- Multi-million-dollar investment lifts domestic cultivation capacity in Germany, strengthening supply for the country’s fast-growing medical market.
- Site renamed Aurora Horizon, positioned as a core node in the group’s European manufacturing network to support broader regional demand growth.
- Expanded areas received an updated EU-GMP license, clearing production scale-up for compliant distribution across European markets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
